3-Iodobenzylguanidine
The therapeutic efficacy of Iobenguane can be decreased when used in combination with Escitalopram.
4-Hydroxybutyric Acid
The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Escitalopram.
Abiraterone
The serum concentration of Escitalopram can be increased when it is combined with Abiraterone.
Advertisement
Acarbose
Escitalopram may increase the hypoglycemic activities of Acarbose.
Acebutolol
Acebutolol may increase the orthostatic hypotensive activities of Escitalopram.
Aceclofenac
Escitalopram may increase the antiplatelet activities of Aceclofenac.
Advertisement
Acenocoumarol
Escitalopram may increase the anticoagulant activities of Acenocoumarol.
Acepromazine
The risk or severity of adverse effects can be increased when Acepromazine is combined with Escitalopram.
Aceprometazine
The risk or severity of adverse effects can be increased when Aceprometazine is combined with Escitalopram.
Advertisement
Acetaminophen
Escitalopram may increase the antiplatelet activities of Acetaminophen.
Acetophenazine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Acetophenazine.
Acetyl salicylate
Escitalopram may increase the antiplatelet activities of Acetylsalicylic acid.
Acetyl Sulfisoxazole
The metabolism of Escitalopram can be decreased when combined with Acetyl sulfisoxazole.
Adrafinil
Escitalopram may decrease the vasoconstricting activities of Adrafinil.
Albiglutide
Escitalopram may increase the hypoglycemic activities of Albiglutide.
Albuterol
Salbutamol may increase the QTc-prolonging activities of Escitalopram.
Alfaxalone
The risk or severity of adverse effects can be increased when Alfaxalone is combined with Escitalopram.
Alfentanil
Alfentanil may increase the serotonergic activities of Escitalopram.
Alfuzosin
Alfuzosin may increase the antihypertensive activities of Escitalopram.
Almotriptan
The risk or severity of adverse effects can be increased when Almotriptan is combined with Escitalopram.
Alogliptin
Escitalopram may increase the hypoglycemic activities of Alogliptin.
Alosetron
Alosetron may increase the serotonergic activities of Escitalopram.
Alphaprodine
Alphaprodine may increase the serotonergic activities of Escitalopram.
Alprazolam
The risk or severity of adverse effects can be increased when Alprazolam is combined with Escitalopram.
Alprenolol
Alprenolol may increase the orthostatic hypotensive activities of Escitalopram.
Amantadine
Amantadine may increase the QTc-prolonging activities of Escitalopram.
Amineptin
The risk or severity of adverse effects can be increased when Amineptine is combined with Escitalopram.
Aminosalicylic Acid
Escitalopram may increase the antiplatelet activities of Aminosalicylic Acid.
Amiodarone
The risk or severity of QTc prolongation can be increased when Amiodarone is combined with Escitalopram.
Amisulpride
The risk or severity of adverse effects can be increased when Amisulpride is combined with Escitalopram.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Escitalopram.
Amlodipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Amlodipine.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Escitalopram.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Escitalopram.
Amphetamine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Amphetamine.
Anagrelide
The risk or severity of QTc prolongation can be increased when Anagrelide is combined with Escitalopram.
Anhydrous Tacrolimus
The metabolism of Tacrolimus can be decreased when combined with Escitalopram.
Antipyrine
Escitalopram may increase the antiplatelet activities of Antipyrine.
Apalutamide
The serum concentration of Escitalopram can be decreased when it is combined with Apalutamide.
Apomorphine
Apomorphine may increase the QTc-prolonging activities of Escitalopram.
Apraclonidine
Escitalopram may decrease the vasoconstricting activities of Apraclonidine.
Aprepitant
The serum concentration of Escitalopram can be increased when it is combined with Aprepitant.
Arbutamine
Escitalopram may decrease the vasoconstricting activities of Arbutamine.
Arformoterol
Arformoterol may increase the QTc-prolonging activities of Escitalopram.
Aripiprazole
Aripiprazole may increase the antihypertensive activities of Escitalopram.
Armodafinil
The metabolism of Escitalopram can be decreased when combined with Armodafinil.
Arsenic Trioxide
The risk or severity of QTc prolongation can be increased when Arsenic trioxide is combined with Escitalopram.
Artemether
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Artemether.
Articaine
The risk or severity of adverse effects can be increased when Articaine is combined with Escitalopram.
Asenapine
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Asenapine.
Asian ginseng extract
Escitalopram may increase the antiplatelet activities of Ginseng.
Aspirin
Escitalopram may increase the antiplatelet activities of Acetylsalicylic acid.
Atazanavir
The metabolism of Escitalopram can be decreased when combined with Atazanavir.
Atenolol
Atenolol may increase the orthostatic hypotensive activities of Escitalopram.
Atomoxetine
Atomoxetine may increase the QTc-prolonging activities of Escitalopram.
Avanafil
Avanafil may increase the hypotensive activities of Escitalopram.
Azelastine
The risk or severity of adverse effects can be increased when Azelastine is combined with Escitalopram.
Azithromycin
Azithromycin may increase the QTc-prolonging activities of Escitalopram.
Baclofen
The risk or severity of adverse effects can be increased when Baclofen is combined with Escitalopram.
Balsalazide
Escitalopram may increase the antiplatelet activities of Balsalazide.
Bambuterol
Escitalopram may decrease the vasoconstricting activities of Bambuterol.
Barbital
The risk or severity of adverse effects can be increased when Barbital is combined with Escitalopram.
Bedaquiline
Bedaquiline may increase the QTc-prolonging activities of Escitalopram.
Bencyclane
The risk or severity of hypotension can be increased when Escitalopram is combined with Bencyclane.
Bendroflumethiazide
Escitalopram may increase the hyponatremic activities of Bendroflumethiazide.
Benoxinate
The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Escitalopram.
Benperidol
The risk or severity of adverse effects can be increased when Benperidol is combined with Escitalopram.
Benzocaine
The risk or severity of adverse effects can be increased when Benzocaine is combined with Escitalopram.
Benzphetamine
Escitalopram may decrease the vasoconstricting activities of Benzphetamine.
Benzthiazide
Escitalopram may increase the hyponatremic activities of Benzthiazide.
Benzyl Alcohol
The risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Escitalopram.
Benzylpenicilloyl polylysine
Escitalopram may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.
Bepridil
The risk or severity of hypotension can be increased when Escitalopram is combined with Bepridil.
BETAHISTINE
The therapeutic efficacy of Betahistine can be decreased when used in combination with Escitalopram.
Betaxolol
Betaxolol may increase the orthostatic hypotensive activities of Escitalopram.
Betrixaban
The risk or severity of bleeding can be increased when Betrixaban is combined with Escitalopram.
Bioallethrin
The risk or severity of hypotension can be increased when Escitalopram is combined with Bioallethrin.
Bisoprolol
Bisoprolol may increase the orthostatic hypotensive activities of Escitalopram.
Bitolterol
Escitalopram may decrease the vasoconstricting activities of Bitolterol.
Bitolterol Mesylate
Escitalopram may decrease the vasoconstricting activities of Bitolterol.
Boceprevir
The serum concentration of Escitalopram can be decreased when it is combined with Boceprevir.
Bopindolol
Bopindolol may increase the orthostatic hypotensive activities of Escitalopram.
Bortezomib
Bortezomib may increase the QTc-prolonging activities of Escitalopram.
Bosentan
The serum concentration of Escitalopram can be decreased when it is combined with Bosentan.
Bosentan Anhydrous
The serum concentration of Escitalopram can be decreased when it is combined with Bosentan.
Brexpiprazole
The risk or severity of adverse effects can be increased when Escitalopram is combined with Brexpiprazole.
Brimonidine
The risk or severity of adverse effects can be increased when Brimonidine is combined with Escitalopram.
Bromazepam
The risk or severity of adverse effects can be increased when Bromazepam is combined with Escitalopram.
Bromfenac
Escitalopram may increase the antiplatelet activities of Bromfenac.
Bromocriptine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Bromocriptine.
Bromperidol
The risk or severity of adverse effects can be increased when Bromperidol is combined with Escitalopram.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Escitalopram.
Brotizolam
The risk or severity of adverse effects can be increased when Brotizolam is combined with Escitalopram.
Bufexamac
Escitalopram may increase the antiplatelet activities of Bufexamac.
Bunazosin
Bunazosin may increase the antihypertensive activities of Escitalopram.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Escitalopram.
Bupranolol
Bupranolol may increase the orthostatic hypotensive activities of Escitalopram.
Buprenorphine
Buprenorphine may increase the serotonergic activities of Escitalopram.
Bupropion
The metabolism of Escitalopram can be decreased when combined with Bupropion.
Buserelin
Buserelin may increase the QTc-prolonging activities of Escitalopram.
Buspirone
Buspirone may increase the serotonergic activities of Escitalopram.
Butabarbital
The risk or severity of adverse effects can be increased when Butabarbital is combined with Escitalopram.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Escitalopram.
Butamben
The risk or severity of adverse effects can be increased when Butamben is combined with Escitalopram.
Butobarbital
The risk or severity of adverse effects can be increased when Butethal is combined with Escitalopram.
Butorphanol
Butorphanol may increase the serotonergic activities of Escitalopram.
Butriptyline
The risk or severity of adverse effects can be increased when Butriptyline is combined with Escitalopram.
Cabergoline
The risk or severity of adverse effects can be increased when Cabergoline is combined with Escitalopram.
Canagliflozin
Escitalopram may increase the hypoglycemic activities of Canagliflozin.
Canagliflozin Anhydrous
Escitalopram may increase the hypoglycemic activities of Canagliflozin.
Capsaicin
Escitalopram may increase the antiplatelet activities of Capsaicin.
Carbamazepine
The metabolism of Carbamazepine can be decreased when combined with Escitalopram.
Carbinoxamine
The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Escitalopram.
Cariprazine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Cariprazine.
Carisoprodol
The risk or severity of adverse effects can be increased when Carisoprodol is combined with Escitalopram.
Carprofen
Escitalopram may increase the antiplatelet activities of Carprofen.
Carteolol
Carteolol may increase the orthostatic hypotensive activities of Escitalopram.
Carvedilol
Carvedilol may increase the antihypertensive activities of Escitalopram.
Celecoxib
Escitalopram may increase the antiplatelet activities of Celecoxib.
Celiprolol
Celiprolol may increase the orthostatic hypotensive activities of Escitalopram.
Ceritinib
The serum concentration of Escitalopram can be increased when it is combined with Ceritinib.
Cetirizine
The risk or severity of adverse effects can be increased when Cetirizine is combined with Escitalopram.
Chloral Hydrate
The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Escitalopram.
Chloramphenicol
The metabolism of Escitalopram can be decreased when combined with Chloramphenicol.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Escitalopram.
Chlormethiazole
The risk or severity of adverse effects can be increased when clomethiazole is combined with Escitalopram.
Chlormezanone
The risk or severity of adverse effects can be increased when Chlormezanone is combined with Escitalopram.
Chloroprocaine
The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Escitalopram.
Chloroquine
Chloroquine may increase the QTc-prolonging activities of Escitalopram.
Chlorothiazide
Escitalopram may increase the hyponatremic activities of Chlorothiazide.
Chlorphenesin
Escitalopram may increase the antiplatelet activities of Chlorphenesin.
Chlorpheniramine
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Escitalopram.
CHLORPHENIRAMINE POLISTIREX
The risk or severity of adverse effects can be increased when Chlorphenamine is combined with Escitalopram.
Chlorpromazine
Chlorpromazine may increase the QTc-prolonging activities of Escitalopram.
Chlorpropamide
Escitalopram may increase the hypoglycemic activities of Chlorpropamide.
Chlorprothixene
The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Escitalopram.
Chlorthalidone
Escitalopram may increase the hyponatremic activities of Chlorthalidone.
Chlorzoxazone
The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Escitalopram.
Cholecalciferol
The metabolism of Escitalopram can be decreased when combined with Cholecalciferol.
Choline Magnesium Trisalicyclate
Escitalopram may increase the antiplatelet activities of Choline magnesium trisalicylate.
Cimetidine
The serum concentration of Escitalopram can be increased when it is combined with Cimetidine.
Cinacalcet
The metabolism of Escitalopram can be decreased when combined with Cinacalcet.
Cinnarizine
The risk or severity of hypotension can be increased when Escitalopram is combined with Cinnarizine.
Ciprofloxacin
Ciprofloxacin may increase the QTc-prolonging activities of Escitalopram.
Cisapride
The risk or severity of QTc prolongation can be increased when Cisapride is combined with Escitalopram.
Cisplatin
Escitalopram may increase the antiplatelet activities of Cisplatin.
Citalopram
The risk or severity of QTc prolongation can be increased when Citalopram is combined with Escitalopram.
Clarithromycin
Clarithromycin may increase the QTc-prolonging activities of Escitalopram.
Clemastine
The metabolism of Escitalopram can be decreased when combined with Clemastine.
Clenbuterol
Escitalopram may decrease the vasoconstricting activities of Clenbuterol.
Clevidipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of hypotension can be increased when Escitalopram is combined with Clevidipine.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram.
Clidinium bromide
The risk or severity of adverse effects can be increased when Clidinium is combined with Escitalopram.
Clobazam
The metabolism of Escitalopram can be decreased when combined with Clobazam.
Clodronic Acid
Escitalopram may increase the antiplatelet activities of Clodronic Acid.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Escitalopram.
Clonazepam
The risk or severity of adverse effects can be increased when Clonazepam is combined with Escitalopram.
Clonidine
The risk or severity of adverse effects can be increased when Clonidine is combined with Escitalopram.
Clorazepate
The risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.
CLORAZEPIC ACID
The risk or severity of adverse effects can be increased when Clorazepate is combined with Escitalopram.
Clotrimazole
The metabolism of Escitalopram can be decreased when combined with Clotrimazole.
Clozapine
The serum concentration of Clozapine can be increased when it is combined with Escitalopram.
Cobicistat
The serum concentration of Escitalopram can be increased when it is combined with Cobicistat.
Cocaine
The metabolism of Escitalopram can be decreased when combined with Cocaine.
Codeine
Codeine may increase the serotonergic activities of Escitalopram.
Codeine Anhydrous
Codeine may increase the serotonergic activities of Escitalopram.
CODEINE POLISTIREX
Codeine may increase the serotonergic activities of Escitalopram.
Conivaptan
The serum concentration of Conivaptan can be increased when it is combined with Escitalopram.
Crizotinib
Crizotinib may increase the QTc-prolonging activities of Escitalopram.
Curcumin
The metabolism of Escitalopram can be decreased when combined with Curcumin.
Cyamemazine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Cyamemazine.
Cyclandelate
The risk or severity of hypotension can be increased when Escitalopram is combined with Cyclandelate.
Cyclizine
The risk or severity of adverse effects can be increased when Cyclizine is combined with Escitalopram.
Cyclobenzaprine
The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.
Cyclopenthiazide
Escitalopram may increase the hyponatremic activities of Cyclopenthiazide.
Cyclosporine
The metabolism of Escitalopram can be decreased when combined with Cyclosporine.
Cyproheptadine
The therapeutic efficacy of Escitalopram can be decreased when used in combination with Cyproheptadine.
Dabrafenib
The serum concentration of Escitalopram can be decreased when it is combined with Dabrafenib.
Dantrolene
The risk or severity of adverse effects can be increased when Dantrolene is combined with Escitalopram.
Dapagliflozin
Escitalopram may increase the hypoglycemic activities of Dapagliflozin.
Dapiprazole
The risk or severity of adverse effects can be increased when Dapiprazole is combined with Escitalopram.
Darifenacin
The metabolism of Escitalopram can be decreased when combined with Darifenacin.
Darunavir
The serum concentration of Escitalopram can be increased when it is combined with Darunavir.
Dasatinib
The serum concentration of Escitalopram can be increased when it is combined with Dasatinib.
Dasatinib Anhydrous
The serum concentration of Escitalopram can be increased when it is combined with Dasatinib.
Deferasirox
The serum concentration of Escitalopram can be decreased when it is combined with Deferasirox.
Degarelix
Degarelix may increase the QTc-prolonging activities of Escitalopram.
Delavirdine
The metabolism of Escitalopram can be decreased when combined with Delavirdine.
Desflurane
Desflurane may increase the QTc-prolonging activities of Escitalopram.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Escitalopram.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Escitalopram.
Desmopressin
The risk or severity of adverse effects can be increased when Escitalopram is combined with Desmopressin.
Desvenlafaxine
Desvenlafaxine may increase the serotonergic activities of Escitalopram.
Deutetrabenazine
Escitalopram may increase the QTc-prolonging activities of Deutetrabenazine.
Dexbrompheniramine
The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Escitalopram.
Dexketoprofen
Escitalopram may increase the antiplatelet activities of Dexketoprofen.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Escitalopram.
Dextroamphetamine
Escitalopram may increase the antihypertensive activities of Dextroamphetamine.
Dextromethorphan
Escitalopram may increase the serotonergic activities of Dextromethorphan.
Dextromoramide
Dextromoramide may increase the serotonergic activities of Escitalopram.
Dezocine
Dezocine may increase the serotonergic activities of Escitalopram.
Diazepam
The risk or severity of adverse effects can be increased when Diazepam is combined with Escitalopram.
Dibucaine
The risk or severity of adverse effects can be increased when Cinchocaine is combined with Escitalopram.
Diclofenac
Escitalopram may increase the antiplatelet activities of Diclofenac.
Dicumarol
Escitalopram may increase the anticoagulant activities of Dicoumarol.
Diethylpropion
Diethylpropion may decrease the sedative activities of Escitalopram.
Difenoxin
The risk or severity of adverse effects can be increased when Difenoxin is combined with Escitalopram.
Diflunisal
Escitalopram may increase the antiplatelet activities of Diflunisal.
Dihydrocodeine
Dihydrocodeine may increase the serotonergic activities of Escitalopram.
Dihydroergotamine
The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Escitalopram.
Diltiazem
The metabolism of Escitalopram can be decreased when combined with Diltiazem.
Dimenhydrinate
The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Escitalopram.
Diphenhydramine
Diphenhydramine may increase the QTc-prolonging activities of Escitalopram.
Diphenoxylate
Diphenoxylate may increase the serotonergic activities of Escitalopram.
Dipivefrin
Escitalopram may decrease the vasoconstricting activities of Dipivefrin.
Dipyridamole
Dipyridamole may increase the hypotensive activities of Escitalopram.
Disopyramide
The risk or severity of QTc prolongation can be increased when Disopyramide is combined with Escitalopram.
Dobutamine
Escitalopram may decrease the vasoconstricting activities of Dobutamine.
Dofetilide
The risk or severity of QTc prolongation can be increased when Dofetilide is combined with Escitalopram.
Dolasetron
Dolasetron may increase the QTc-prolonging activities of Escitalopram.
Domperidone
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Domperidone.
Dopexamine
Escitalopram may decrease the vasoconstricting activities of Dopexamine.
Dothiepin
The serum concentration of Dosulepin can be increased when it is combined with Escitalopram.
Doxazosin
Doxazosin may increase the antihypertensive activities of Escitalopram.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Escitalopram.
Doxycycline
The metabolism of Escitalopram can be decreased when combined with Doxycycline.
Doxycycline Anhydrous
The metabolism of Escitalopram can be decreased when combined with Doxycycline.
Doxylamine
The risk or severity of adverse effects can be increased when Doxylamine is combined with Escitalopram.
Dronedarone
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Dronedarone.
Droperidol
Droperidol may increase the QTc-prolonging activities of Escitalopram.
Drospirenone
Escitalopram may increase the antiplatelet activities of Drospirenone.
Droxicam
Escitalopram may increase the antiplatelet activities of Droxicam.
Droxidopa
Escitalopram may decrease the vasoconstricting activities of Droxidopa.
Dulaglutide
Escitalopram may increase the hypoglycemic activities of Dulaglutide.
Duloxetine
Duloxetine may increase the serotonergic activities of Escitalopram.
Dyclonine
The risk or severity of adverse effects can be increased when Dyclonine is combined with Escitalopram.
Efavirenz
The metabolism of Escitalopram can be decreased when combined with Efavirenz.
Eicosapentaenoic Acid
Escitalopram may increase the antiplatelet activities of Icosapent.
Eletriptan
The risk or severity of adverse effects can be increased when Eletriptan is combined with Escitalopram.
Eliglustat
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Eliglustat.
Empagliflozin
Escitalopram may increase the hypoglycemic activities of Empagliflozin.
Enflurane
The risk or severity of adverse effects can be increased when Enflurane is combined with Escitalopram.
Entacapone
The risk or severity of adverse effects can be increased when Entacapone is combined with Escitalopram.
Enzalutamide
The serum concentration of Escitalopram can be decreased when it is combined with Enzalutamide.
Ephedrine
Escitalopram may decrease the vasoconstricting activities of Ephedrine.
Epinastine
Escitalopram may decrease the vasoconstricting activities of Epinastine.
Epinephrine
Escitalopram may increase the antihypertensive activities of Epinephrine.
ergoloid mesylates, USP
The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Escitalopram.
Ergonovine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Ergonovine.
Ergotamine
The risk or severity of adverse effects can be increased when Ergotamine is combined with Escitalopram.
Eribulin
Eribulin may increase the QTc-prolonging activities of Escitalopram.
Erythromycin
Erythromycin may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine Acetate
The metabolism of Escitalopram can be decreased when combined with Eslicarbazepine acetate.
Esmolol
Esmolol may increase the orthostatic hypotensive activities of Escitalopram.
Esomeprazole
The metabolism of Escitalopram can be decreased when combined with Esomeprazole.
Estazolam
The risk or severity of adverse effects can be increased when Estazolam is combined with Escitalopram.
Eszopiclone
The risk or severity of adverse effects can be increased when Eszopiclone is combined with Escitalopram.
Etanercept
Escitalopram may increase the antiplatelet activities of Etanercept.
Ethanol
The risk or severity of adverse effects can be increased when Ethanol is combined with Escitalopram.
Ethchlorvynol
The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Escitalopram.
Ethosuximide
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Escitalopram.
Ethotoin
The risk or severity of adverse effects can be increased when Ethotoin is combined with Escitalopram.
Ethyl Chloride
The risk or severity of adverse effects can be increased when Ethyl chloride is combined with Escitalopram.
Ethyl Loflazepate
The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Escitalopram.
Ethylmorphine
Ethylmorphine may increase the serotonergic activities of Escitalopram.
Etidocaine
The risk or severity of adverse effects can be increased when Etidocaine is combined with Escitalopram.
Etifoxine
The risk or severity of adverse effects can be increased when Etifoxine is combined with Escitalopram.
Etilefrine
Escitalopram may decrease the vasoconstricting activities of Etilefrine.
Etodolac
Escitalopram may increase the antiplatelet activities of Etodolac.
Etomidate
The risk or severity of adverse effects can be increased when Etomidate is combined with Escitalopram.
Etoricoxib
Escitalopram may increase the antiplatelet activities of Etoricoxib.
Etravirine
The metabolism of Escitalopram can be decreased when combined with Etravirine.
Exenatide
Escitalopram may increase the hypoglycemic activities of Exenatide.
Ezogabine
Ezogabine may increase the QTc-prolonging activities of Escitalopram.
Famotidine
Famotidine may increase the QTc-prolonging activities of Escitalopram.
Felbamate
Felbamate may increase the QTc-prolonging activities of Escitalopram.
Felodipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Felodipine.
Fendiline
The risk or severity of hypotension can be increased when Escitalopram is combined with Fendiline.
Fenfluramine
Escitalopram may increase the serotonergic activities of Fenfluramine.
Fenoprofen
Escitalopram may increase the antiplatelet activities of Fenoprofen.
Fenoterol
Escitalopram may decrease the vasoconstricting activities of Fenoterol.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Escitalopram.
Fesoterodine
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Escitalopram.
Fexofenadine
The risk or severity of adverse effects can be increased when Fexofenadine is combined with Escitalopram.
Fingolimod
Fingolimod may increase the QTc-prolonging activities of Escitalopram.
Fish Oils
Escitalopram may increase the antiplatelet activities of Fish oil.
Flecainide
Flecainide may increase the QTc-prolonging activities of Escitalopram.
Flibanserin
The risk or severity of adverse effects can be increased when Flibanserin is combined with Escitalopram.
Fluconazole
The metabolism of Escitalopram can be decreased when combined with Fluconazole.
Fluindione
Escitalopram may increase the anticoagulant activities of Fluindione.
Flunarizine
The risk or severity of adverse effects can be increased when Flunarizine is combined with Escitalopram.
Flunitrazepam
The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Escitalopram.
Fluoxetine
The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Escitalopram.
Flupenthixol
The risk or severity of QTc prolongation can be increased when Flupentixol is combined with Escitalopram.
Fluphenazine
The risk or severity of adverse effects can be increased when Fluphenazine is combined with Escitalopram.
Flurazepam
The risk or severity of adverse effects can be increased when Flurazepam is combined with Escitalopram.
Flurbiprofen
Escitalopram may increase the antiplatelet activities of Flurbiprofen.
Fluspirilene
The risk or severity of adverse effects can be increased when Fluspirilene is combined with Escitalopram.
Fluticasone propionate
The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Escitalopram.
Fluvoxamine
The metabolism of Escitalopram can be decreased when combined with Fluvoxamine.
Formoterol
Formoterol may increase the QTc-prolonging activities of Escitalopram.
Fosamprenavir
The metabolism of Escitalopram can be decreased when combined with Fosamprenavir.
Fosaprepitant
The serum concentration of Escitalopram can be increased when it is combined with Fosaprepitant.
Foscarnet
Foscarnet may increase the QTc-prolonging activities of Escitalopram.
Fosphenytoin
The metabolism of Escitalopram can be increased when combined with Fosphenytoin.
Fospropofol
The risk or severity of adverse effects can be increased when Fospropofol is combined with Escitalopram.
Fostamatinib
Fostamatinib may increase the hypotensive activities of Escitalopram.
Frovatriptan
The risk or severity of adverse effects can be increased when Frovatriptan is combined with Escitalopram.
Furazolidone
Furazolidone may increase the serotonergic activities of Escitalopram.
Fusidate
The serum concentration of Escitalopram can be increased when it is combined with Fusidic Acid.
Fusidic Acid
The serum concentration of Escitalopram can be increased when it is combined with Fusidic Acid.
Gabapentin
The risk or severity of adverse effects can be increased when Gabapentin is combined with Escitalopram.
Gabapentin Enacarbil
The risk or severity of adverse effects can be increased when Gabapentin Enacarbil is combined with Escitalopram.
Gadobenate
Gadobenic acid may increase the QTc-prolonging activities of Escitalopram.
Galantamine
The metabolism of Galantamine can be decreased when combined with Escitalopram.
Gallopamil
The risk or severity of hypotension can be increased when Escitalopram is combined with Gallopamil.
Gemfibrozil
The metabolism of Escitalopram can be decreased when combined with Gemfibrozil.
Gemifloxacin
Gemifloxacin may increase the QTc-prolonging activities of Escitalopram.
Gemifloxacin Mesylate
Gemifloxacin may increase the QTc-prolonging activities of Escitalopram.
Ginseng Preparation
Escitalopram may increase the antiplatelet activities of Ginseng.
Gliclazide
Escitalopram may increase the hypoglycemic activities of Gliclazide.
Glimepiride
Escitalopram may increase the hypoglycemic activities of Glimepiride.
Glipizide
Escitalopram may increase the hypoglycemic activities of Glipizide.
Glutethimide
The risk or severity of adverse effects can be increased when Glutethimide is combined with Escitalopram.
Glyburide
Escitalopram may increase the hypoglycemic activities of Glyburide.
Goserelin
Goserelin may increase the QTc-prolonging activities of Escitalopram.
Granisetron
Granisetron may increase the QTc-prolonging activities of Escitalopram.
Guanabenz
Escitalopram may decrease the vasoconstricting activities of Guanabenz.
Guanfacine
The risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.
Halazepam
The risk or severity of adverse effects can be increased when Halazepam is combined with Escitalopram.
Haloperidol
Haloperidol may increase the QTc-prolonging activities of Escitalopram.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Escitalopram.
Heroin
Heroin may increase the serotonergic activities of Escitalopram.
Hexobarbital
The risk or severity of adverse effects can be increased when Hexobarbital is combined with Escitalopram.
Hexoprenaline
Escitalopram may decrease the vasoconstricting activities of Hexoprenaline.
Histrelin
Histrelin may increase the QTc-prolonging activities of Escitalopram.
Hyaluronidase
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Escitalopram.
Hyaluronidase, Ovine
The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Escitalopram.
Hydrochlorothiazide
Escitalopram may increase the hyponatremic activities of Hydrochlorothiazide.
Hydrocodone
Hydrocodone may increase the serotonergic activities of Escitalopram.
HYDROCODONE POLISTIREX
Hydrocodone may increase the serotonergic activities of Escitalopram.
Hydroflumethiazide
Escitalopram may increase the hyponatremic activities of Hydroflumethiazide.
Hydromorphone
Hydromorphone may increase the serotonergic activities of Escitalopram.
Hydroxyzine
Hydroxyzine may increase the QTc-prolonging activities of Escitalopram.
Hypoxis hemerocallidea root extract
The serum concentration of Escitalopram can be decreased when it is combined with St. John's Wort.
Ibandronate
Ibandronate may increase the QTc-prolonging activities of Escitalopram.
Ibandronic Acid
Ibandronate may increase the QTc-prolonging activities of Escitalopram.
Ibuprofen
Escitalopram may increase the antiplatelet activities of Ibuprofen.
Ibutilide
The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Escitalopram.
Idelalisib
The metabolism of Escitalopram can be decreased when combined with Idelalisib.
Iloperidone
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Iloperidone.
Imatinib
The metabolism of Escitalopram can be decreased when combined with Imatinib.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Escitalopram.
Inamrinone
The risk or severity of hypotension can be increased when Escitalopram is combined with Amrinone.
Indacaterol
Indacaterol may increase the QTc-prolonging activities of Escitalopram.
Indapamide
Indapamide may increase the QTc-prolonging activities of Escitalopram.
Indinavir
The metabolism of Escitalopram can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Escitalopram can be decreased when combined with Indinavir.
Indomethacin
Escitalopram may increase the antiplatelet activities of Indomethacin.
Indoramin
Indoramin may increase the antihypertensive activities of Escitalopram.
Insulin Detemir
Escitalopram may increase the hypoglycemic activities of Insulin Detemir.
Insulin Glargine
Escitalopram may increase the hypoglycemic activities of Insulin Glargine.
insulin human, rDNA origin
Escitalopram may increase the hypoglycemic activities of Insulin Human.
Insulin Lispro
Escitalopram may increase the hypoglycemic activities of Insulin Lispro.
Insulin, Aspart Protamine, Human
Escitalopram may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Aspart, Human
Escitalopram may increase the hypoglycemic activities of Insulin Aspart.
Insulin, Glulisine, Human
Escitalopram may increase the hypoglycemic activities of Insulin Glulisine.
Insulin, Protamine Lispro, Human
Escitalopram may increase the hypoglycemic activities of Insulin Lispro.
Ioflupane I-123
Escitalopram may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.
Iproniazid
Iproniazid may increase the serotonergic activities of Escitalopram.
Isavuconazole
The serum concentration of Escitalopram can be increased when it is combined with Isavuconazole.
Isavuconazonium
The metabolism of Escitalopram can be decreased when combined with Isavuconazonium.
Isocarboxazid
The therapeutic efficacy of Escitalopram can be increased when used in combination with Isocarboxazid.
Isoetharine
Escitalopram may decrease the vasoconstricting activities of Isoetarine.
Isoflurane
Isoflurane may increase the QTc-prolonging activities of Escitalopram.
Isometheptene
Escitalopram may decrease the vasoconstricting activities of Isometheptene.
Isoniazid
The metabolism of Escitalopram can be decreased when combined with Isoniazid.
Isoproterenol
Escitalopram may decrease the vasoconstricting activities of Isoprenaline.
Isoxsuprine
Escitalopram may decrease the vasoconstricting activities of Isoxsuprine.
Isradipine
Isradipine may increase the QTc-prolonging activities of Escitalopram.
Itraconazole
The metabolism of Escitalopram can be decreased when combined with Itraconazole.
Ivabradine
Escitalopram may increase the QTc-prolonging activities of Ivabradine.
Ivacaftor
The serum concentration of Escitalopram can be increased when it is combined with Ivacaftor.
Ketamine
The risk or severity of adverse effects can be increased when Ketamine is combined with Escitalopram.
Ketazolam
The risk or severity of adverse effects can be increased when Ketazolam is combined with Escitalopram.
Ketoconazole
The metabolism of Escitalopram can be decreased when combined with Ketoconazole.
Ketoprofen
Escitalopram may increase the antiplatelet activities of Ketoprofen.
Ketorolac
Escitalopram may increase the antiplatelet activities of Ketorolac.
Korean ginseng preparation
Escitalopram may increase the antiplatelet activities of Ginseng.
KOREAN GINSENG ROOT
Escitalopram may increase the antiplatelet activities of Ginseng.
Korean Ginseng Root Extract
Escitalopram may increase the antiplatelet activities of Ginseng.
Labetalol
Labetalol may increase the antihypertensive activities of Escitalopram.
Lacidipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Lacidipine.
Lamotrigine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Lamotrigine.
Lapatinib
Lapatinib may increase the QTc-prolonging activities of Escitalopram.
Lenvatinib
Lenvatinib may increase the QTc-prolonging activities of Escitalopram.
Lenvatinib Mesylate
Lenvatinib may increase the QTc-prolonging activities of Escitalopram.
Lercanidipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Lercanidipine.
Leuprolide
Leuprolide may increase the QTc-prolonging activities of Escitalopram.
Levalbuterol
Escitalopram may decrease the vasoconstricting activities of Levosalbutamol.
Levetiracetam
The risk or severity of adverse effects can be increased when Levetiracetam is combined with Escitalopram.
Levobetaxolol
Levobetaxolol may increase the orthostatic hypotensive activities of Escitalopram.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Escitalopram.
Levocabastine
The risk or severity of adverse effects can be increased when Levocabastine is combined with Escitalopram.
Levocetirizine
The risk or severity of adverse effects can be increased when Levocetirizine is combined with Escitalopram.
Levodopa
The risk or severity of adverse effects can be increased when Levodopa is combined with Escitalopram.
Levofloxacin
Levofloxacin may increase the QTc-prolonging activities of Escitalopram.
Levofloxacin Anhydrous
Levofloxacin may increase the QTc-prolonging activities of Escitalopram.
LEVOMENTHOL
The risk or severity of hypotension can be increased when Escitalopram is combined with Menthol.
Levomethadyl
Levomethadyl Acetate may increase the serotonergic activities of Escitalopram.
Levomilnacipran
Levomilnacipran may increase the serotonergic activities of Escitalopram.
Levorphanol
Levorphanol may increase the serotonergic activities of Escitalopram.
Levothyroxine
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Escitalopram.
Lidocaine
The risk or severity of adverse effects can be increased when Lidocaine is combined with Escitalopram.
Linezolid
Linezolid may increase the serotonergic activities of Escitalopram.
Liothyronine
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Escitalopram.
Liraglutide
Escitalopram may increase the hypoglycemic activities of Liraglutide.
Lisdexamfetamine
Escitalopram may increase the antihypertensive activities of Lisdexamfetamine.
Lisdexamfetamine Dimesylate
Escitalopram may increase the antihypertensive activities of Lisdexamfetamine.
Lithium
Lithium may increase the serotonergic activities of Escitalopram.
Lithium Cation
Lithium may increase the serotonergic activities of Escitalopram.
Lofexidine
Escitalopram may decrease the vasoconstricting activities of Lofexidine.
Loperamide
The risk or severity of hypotension can be increased when Escitalopram is combined with Loperamide.
Lopinavir
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Lopinavir.
Loratadine
The risk or severity of adverse effects can be increased when Loratadine is combined with Escitalopram.
Lorazepam
The risk or severity of adverse effects can be increased when Lorazepam is combined with Escitalopram.
Lorcaserin
The risk or severity of adverse effects can be increased when Escitalopram is combined with Lorcaserin.
Lormetazepam
The risk or severity of adverse effects can be increased when Lormetazepam is combined with Escitalopram.
Lornoxicam
Escitalopram may increase the antiplatelet activities of Lornoxicam.
Lovastatin
The metabolism of Escitalopram can be decreased when combined with Lovastatin.
Loxapine
The risk or severity of adverse effects can be increased when Loxapine is combined with Escitalopram.
Luliconazole
The serum concentration of Escitalopram can be increased when it is combined with Luliconazole.
Lumacaftor
The serum concentration of Escitalopram can be decreased when it is combined with Lumacaftor.
Lumefantrine
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Lumefantrine.
Lurasidone
The risk or severity of adverse effects can be increased when Lurasidone is combined with Escitalopram.
Macimorelin
Escitalopram may increase the QTc-prolonging activities of Macimorelin.
Magnesium Salicylate
Escitalopram may increase the antiplatelet activities of Magnesium salicylate.
Magnesium Sulfate
The risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Escitalopram.
MAGNESIUM SULFATE ANHYDROUS
The risk or severity of adverse effects can be increased when Magnesium sulfate is combined with Escitalopram.
Manidipine
The metabolism of Escitalopram can be decreased when combined with Manidipine.
Maprotiline
Maprotiline may increase the QTc-prolonging activities of Escitalopram.
Mecasermin
Escitalopram may increase the hypoglycemic activities of Mecasermin.
Mecasermin Rinfabate
Escitalopram may increase the hypoglycemic activities of Mecasermin.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Escitalopram.
Meclofenamate
Escitalopram may increase the antiplatelet activities of Meclofenamic acid.
Meclofenamic Acid
Escitalopram may increase the antiplatelet activities of Meclofenamic acid.
Mefenamic Acid
Escitalopram may increase the antiplatelet activities of Mefenamic acid.
Mefloquine
Mefloquine may increase the QTc-prolonging activities of Escitalopram.
Melatonin
The risk or severity of adverse effects can be increased when Melatonin is combined with Escitalopram.
MELITRACEN
The risk or severity of adverse effects can be increased when Melitracen is combined with Escitalopram.
Meloxicam
Escitalopram may increase the antiplatelet activities of Meloxicam.
Menthol
The risk or severity of hypotension can be increased when Escitalopram is combined with Menthol.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Escitalopram.
Mephentermine
Escitalopram may decrease the vasoconstricting activities of Mephentermine.
Mephobarbital
The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Escitalopram.
Mepindolol
Mepindolol may increase the orthostatic hypotensive activities of Escitalopram.
Mepirodipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Barnidipine.
Mepivacaine
The risk or severity of adverse effects can be increased when Mepivacaine is combined with Escitalopram.
Meprobamate
The risk or severity of adverse effects can be increased when Meprobamate is combined with Escitalopram.
Mesalamine
Escitalopram may increase the antiplatelet activities of Mesalazine.
Mesoridazine
The risk or severity of adverse effects can be increased when Mesoridazine is combined with Escitalopram.
Metaproterenol
Escitalopram may decrease the vasoconstricting activities of Orciprenaline.
Metaraminol
Escitalopram may decrease the vasoconstricting activities of Metaraminol.
Metaxalone
The risk or severity of adverse effects can be increased when Metaxalone is combined with Escitalopram.
Metformin
Escitalopram may increase the hypoglycemic activities of Metformin.
Methadone
The metabolism of Methadone can be decreased when combined with Escitalopram.
Methadyl Acetate
Methadyl Acetate may increase the serotonergic activities of Escitalopram.
Methamphetamine
Escitalopram may decrease the vasoconstricting activities of Methamphetamine.
Methapyrilene
The risk or severity of adverse effects can be increased when Methapyrilene is combined with Escitalopram.
Methaqualone
The risk or severity of adverse effects can be increased when Methaqualone is combined with Escitalopram.
Methocarbamol
The risk or severity of adverse effects can be increased when Methocarbamol is combined with Escitalopram.
Methohexital
The risk or severity of adverse effects can be increased when Methohexital is combined with Escitalopram.
Methotrimeprazine
The metabolism of Escitalopram can be decreased when combined with Methotrimeprazine.
Methoxamine
Escitalopram may decrease the vasoconstricting activities of Methoxamine.
Methoxyflurane
The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Escitalopram.
Methsuximide
The risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.
Methyclothiazide
Escitalopram may increase the hyponatremic activities of Methyclothiazide.
Methyldopa
Escitalopram may decrease the vasoconstricting activities of Methyldopa.
METHYLDOPA ANHYDROUS
Escitalopram may decrease the vasoconstricting activities of Methyldopa.
Methylene blue
Escitalopram may increase the serotonergic activities of Methylene blue.
METHYLEPHEDRINE, DL-
Escitalopram may decrease the vasoconstricting activities of DL-Methylephedrine.
Metoclopramide
The risk or severity of adverse effects can be increased when Metoclopramide is combined with Escitalopram.
Metolazone
Escitalopram may increase the hyponatremic activities of Metolazone.
Metoprolol
The serum concentration of Metoprolol can be increased when it is combined with Escitalopram.
Metronidazole
Metronidazole may increase the QTc-prolonging activities of Escitalopram.
Metylperon
The risk or severity of adverse effects can be increased when Melperone is combined with Escitalopram.
Metyrosine
The risk or severity of adverse effects can be increased when Metyrosine is combined with Escitalopram.
Mexiletine
The metabolism of Mexiletine can be decreased when combined with Escitalopram.
Mibefradil
The risk or severity of hypotension can be increased when Escitalopram is combined with Mibefradil.
Midazolam
The risk or severity of adverse effects can be increased when Midazolam is combined with Escitalopram.
Midodrine
Escitalopram may decrease the vasoconstricting activities of Midodrine.
Midostaurin
The metabolism of Escitalopram can be decreased when combined with Midostaurin.
Mifepristone
Escitalopram may increase the QTc-prolonging activities of Mifepristone.
Miglitol
Escitalopram may increase the hypoglycemic activities of Miglitol.
Milnacipran
Milnacipran may increase the serotonergic activities of Escitalopram.
Minaprine
Minaprine may increase the serotonergic activities of Escitalopram.
Mirabegron
Mirabegron may increase the QTc-prolonging activities of Escitalopram.
Mirtazapine
The risk or severity of adverse effects can be increased when Mirtazapine is combined with Escitalopram.
Mitotane
The serum concentration of Escitalopram can be decreased when it is combined with Mitotane.
Moclobemide
The risk or severity of adverse effects can be increased when Escitalopram is combined with Moclobemide.
Modafinil
The metabolism of Escitalopram can be decreased when combined with Modafinil.
Moexipril
Moexipril may increase the QTc-prolonging activities of Escitalopram.
Molindone
The risk or severity of adverse effects can be increased when Molindone is combined with Escitalopram.
Moricizine
The risk or severity of adverse effects can be increased when Moricizine is combined with Escitalopram.
Morniflumate
Escitalopram may increase the antiplatelet activities of Morniflumate.
Morphine
Morphine may increase the serotonergic activities of Escitalopram.
Moxifloxacin
Moxifloxacin may increase the QTc-prolonging activities of Escitalopram.
Moxonidine
Escitalopram may decrease the vasoconstricting activities of Moxonidine.
N-methylephedrine
Escitalopram may decrease the vasoconstricting activities of DL-Methylephedrine.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Escitalopram.
Nabumetone
Escitalopram may increase the antiplatelet activities of Nabumetone.
Nadolol
Nadolol may increase the orthostatic hypotensive activities of Escitalopram.
Nalbuphine
Nalbuphine may increase the serotonergic activities of Escitalopram.
Naphazoline
Escitalopram may decrease the vasoconstricting activities of Naphazoline.
Naproxen
Escitalopram may increase the antiplatelet activities of Naproxen.
Naratriptan
The risk or severity of adverse effects can be increased when Naratriptan is combined with Escitalopram.
Nateglinide
Escitalopram may increase the hypoglycemic activities of Nateglinide.
Nebivolol
Nebivolol may increase the orthostatic hypotensive activities of Escitalopram.
Nefazodone
Nefazodone may increase the antihypertensive activities of Escitalopram.
Nelfinavir
The metabolism of Escitalopram can be decreased when combined with Nelfinavir.
Nepafenac
Escitalopram may increase the antiplatelet activities of Nepafenac.
Netupitant
The serum concentration of Escitalopram can be increased when it is combined with Netupitant.
Nevirapine
The metabolism of Escitalopram can be increased when combined with Nevirapine.
Nialamide
Nialamide may increase the serotonergic activities of Escitalopram.
Nicardipine
Nicardipine may increase the antihypertensive activities of Escitalopram.
Nicergoline
Nicergoline may increase the antihypertensive activities of Escitalopram.
Nifedipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Nifedipine.
Niflumic Acid
Escitalopram may increase the antiplatelet activities of Niflumic Acid.
Nilotinib
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Nilotinib.
Nilvadipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Nilvadipine.
Nimesulide
Escitalopram may increase the antiplatelet activities of Nimesulide.
Nimodipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Nimodipine.
Nisoldipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Nisoldipine.
Nitrazepam
The risk or severity of adverse effects can be increased when Nitrazepam is combined with Escitalopram.
Nitrendipine
The risk or severity of hypotension can be increased when Escitalopram is combined with Nitrendipine.
Nitrous Oxide
The risk or severity of adverse effects can be increased when Nitrous oxide is combined with Escitalopram.
Nordazepam
The risk or severity of adverse effects can be increased when Nordazepam is combined with Escitalopram.
Norepinephrine
Escitalopram may decrease the vasoconstricting activities of Norepinephrine.
Norfloxacin
Norfloxacin may increase the QTc-prolonging activities of Escitalopram.
Norflurane
The risk or severity of adverse effects can be increased when Norflurane is combined with Escitalopram.
Normethadone
Normethadone may increase the serotonergic activities of Escitalopram.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Escitalopram.
Nylidrin
Escitalopram may decrease the vasoconstricting activities of Nylidrin.
Octreotide
Octreotide may increase the QTc-prolonging activities of Escitalopram.
Octylonium
The risk or severity of hypotension can be increased when Escitalopram is combined with Otilonium.
Ofloxacin
Ofloxacin may increase the QTc-prolonging activities of Escitalopram.
Olanzapine
Escitalopram may increase the serotonergic activities of Olanzapine.
Olaparib
The metabolism of Escitalopram can be decreased when combined with Olaparib.
Olodaterol
Olodaterol may increase the QTc-prolonging activities of Escitalopram.
Olopatadine
The risk or severity of adverse effects can be increased when Olopatadine is combined with Escitalopram.
Omeprazole
The serum concentration of Escitalopram can be increased when it is combined with Omeprazole.
Ondansetron
Ondansetron may increase the QTc-prolonging activities of Escitalopram.
Opipramol
The risk or severity of adverse effects can be increased when Opipramol is combined with Escitalopram.
Opium
Opium may increase the serotonergic activities of Escitalopram.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Escitalopram.
Osimertinib
The serum concentration of Escitalopram can be increased when it is combined with Osimertinib.
Oxaprozin
Escitalopram may increase the antiplatelet activities of Oxaprozin.
Oxazepam
The risk or severity of adverse effects can be increased when Oxazepam is combined with Escitalopram.
Oxprenolol
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Escitalopram.
Oxycodone
Oxycodone may increase the serotonergic activities of Escitalopram.
Oxymetazoline
Escitalopram may decrease the vasoconstricting activities of Oxymetazoline.
Oxymorphone
Oxymorphone may increase the serotonergic activities of Escitalopram.
Oxytocin
Oxytocin may increase the QTc-prolonging activities of Escitalopram.
p-Hydroxyamphetamine
Hydroxyamphetamine may decrease the sedative activities of Escitalopram.
Palbociclib
The serum concentration of Escitalopram can be increased when it is combined with Palbociclib.
Paliperidone
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Paliperidone.
Palonosetron
Palonosetron may increase the serotonergic activities of Escitalopram.
Panobinostat
The serum concentration of Escitalopram can be increased when it is combined with Panobinostat.
Pantoprazole
The metabolism of Escitalopram can be decreased when combined with Pantoprazole.
Paraldehyde
The risk or severity of adverse effects can be increased when Paraldehyde is combined with Escitalopram.
Parecoxib
Escitalopram may increase the antiplatelet activities of Parecoxib.
Paregoric
Morphine may increase the serotonergic activities of Escitalopram.
Pargyline
Pargyline may increase the serotonergic activities of Escitalopram.
Paroxetine
The metabolism of Escitalopram can be decreased when combined with Paroxetine.
Pasireotide
Pasireotide may increase the QTc-prolonging activities of Escitalopram.
Pazopanib
Pazopanib may increase the QTc-prolonging activities of Escitalopram.
Peginterferon Alfa-2b
The serum concentration of Escitalopram can be decreased when it is combined with Peginterferon alfa-2b.
Penbutolol
Penbutolol may increase the orthostatic hypotensive activities of Escitalopram.
Pentamidine
Pentamidine may increase the QTc-prolonging activities of Escitalopram.
Pentazocine
Pentazocine may increase the serotonergic activities of Escitalopram.
Pentobarbital
The metabolism of Escitalopram can be increased when combined with Pentobarbital.
Pentoxifylline
Pentoxifylline may increase the hypotensive activities of Escitalopram.
Perampanel
The risk or severity of adverse effects can be increased when Perampanel is combined with Escitalopram.
Perazine
The risk or severity of adverse effects can be increased when Perazine is combined with Escitalopram.
Perflutren
Perflutren may increase the QTc-prolonging activities of Escitalopram.
Pergolide
Escitalopram may decrease the vasoconstricting activities of Pergolide.
Periciazine
Escitalopram may increase the antihypertensive activities of Propericiazine.
Perphenazine
The risk or severity of adverse effects can be increased when Perphenazine is combined with Escitalopram.
Phendimetrazine
Escitalopram may decrease the vasoconstricting activities of Phendimetrazine.
Phenelzine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Phenelzine.
Phenindione
Escitalopram may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Escitalopram can be increased when combined with Phenobarbital.
Phenoxybenzamine
Phenoxybenzamine may increase the antihypertensive activities of Escitalopram.
Phenoxyethanol
The risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Escitalopram.
Phenprocoumon
Escitalopram may increase the anticoagulant activities of Phenprocoumon.
Phentermine
Phentermine may decrease the sedative activities of Escitalopram.
PHENTERMINE RESIN
Phentermine may decrease the sedative activities of Escitalopram.
Phentolamine
Escitalopram may increase the antihypertensive activities of Phentolamine.
Phentolamine Mesylate
Escitalopram may increase the antihypertensive activities of Phentolamine.
Phenylbutazone
Escitalopram may increase the antiplatelet activities of Phenylbutazone.
Phenylephrine
Escitalopram may decrease the vasoconstricting activities of Phenylephrine.
Phenylpropanolamine
Escitalopram may decrease the vasoconstricting activities of Phenylpropanolamine.
Phenytoin
The metabolism of Escitalopram can be increased when combined with Phenytoin.
Pimozide
The risk or severity of QTc prolongation can be increased when Pimozide is combined with Escitalopram.
Pinaverium
The risk or severity of hypotension can be increased when Escitalopram is combined with Pinaverium.
Pindolol
Pindolol may increase the orthostatic hypotensive activities of Escitalopram.
Pioglitazone
Escitalopram may increase the hypoglycemic activities of Pioglitazone.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Escitalopram.
Pipothiazine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Pipotiazine.
Pirbuterol
Escitalopram may decrease the vasoconstricting activities of Pirbuterol.
Pirinitramide
Piritramide may increase the serotonergic activities of Escitalopram.
Piroxicam
Escitalopram may increase the antiplatelet activities of Piroxicam.
Piroxicam-Beta-Cyclodextrin
Escitalopram may increase the antiplatelet activities of Piroxicam.
Pizotyline
Escitalopram may increase the antihypertensive activities of Pizotifen.
Polythiazide
Escitalopram may increase the hyponatremic activities of Polythiazide.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Escitalopram.
Posaconazole
The metabolism of Escitalopram can be decreased when combined with Posaconazole.
Practolol
Practolol may increase the orthostatic hypotensive activities of Escitalopram.
Pramlintide
Escitalopram may increase the hypoglycemic activities of Pramlintide.
Pramoxine
The risk or severity of adverse effects can be increased when Pramocaine is combined with Escitalopram.
Prazepam
The risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram.
Prazosin
Prazosin may increase the antihypertensive activities of Escitalopram.
Pregabalin
The risk or severity of adverse effects can be increased when Pregabalin is combined with Escitalopram.
Prenylamine
The risk or severity of hypotension can be increased when Escitalopram is combined with Prenylamine.
Prilocaine
The risk or severity of adverse effects can be increased when Prilocaine is combined with Escitalopram.
Primaquine
Primaquine may increase the QTc-prolonging activities of Escitalopram.
Primidone
The metabolism of Escitalopram can be increased when combined with Primidone.
Procainamide
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Escitalopram.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Escitalopram.
Procarbazine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Procarbazine.
Procaterol
Escitalopram may decrease the vasoconstricting activities of Procaterol.
Prochlorperazine
The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Escitalopram.
Promazine
Promazine may increase the QTc-prolonging activities of Escitalopram.
Promethazine
Promethazine may increase the QTc-prolonging activities of Escitalopram.
Propafenone
Propafenone may increase the QTc-prolonging activities of Escitalopram.
Proparacaine
The risk or severity of adverse effects can be increased when Proparacaine is combined with Escitalopram.
Propiomazine
Propiomazine may increase the antihypertensive activities of Escitalopram.
Propiverine
Escitalopram may increase the antihypertensive activities of Propiverine.
Propofol
Propofol may increase the QTc-prolonging activities of Escitalopram.
Propoxyphene
Dextropropoxyphene may increase the serotonergic activities of Escitalopram.
Propranolol
Propranolol may increase the orthostatic hypotensive activities of Escitalopram.
Prothipendyl
The risk or severity of adverse effects can be increased when Escitalopram is combined with Prothipendyl.
Protriptyline
The risk or severity of adverse effects can be increased when Protriptyline is combined with Escitalopram.
Pseudoephedrine
Escitalopram may decrease the vasoconstricting activities of Pseudoephedrine.
Quazepam
The risk or severity of adverse effects can be increased when Quazepam is combined with Escitalopram.
Quetiapine
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Quetiapine.
Quinethazone
Escitalopram may increase the hyponatremic activities of Quinethazone.
Quinidine
The risk or severity of QTc prolongation can be increased when Quinidine is combined with Escitalopram.
Quinine
The risk or severity of QTc prolongation can be increased when Quinine is combined with Escitalopram.
Racepinephrine
Escitalopram may increase the antihypertensive activities of Racepinephrine.
Ramelteon
The risk or severity of adverse effects can be increased when Ramelteon is combined with Escitalopram.
Ranolazine
Ranolazine may increase the QTc-prolonging activities of Escitalopram.
Rasagiline
The risk or severity of adverse effects can be increased when Escitalopram is combined with Rasagiline.
Regular Insulin, Human
Escitalopram may increase the hypoglycemic activities of Insulin Human.
Remifentanil
Remifentanil may increase the serotonergic activities of Escitalopram.
Remoxipride
The risk or severity of adverse effects can be increased when Remoxipride is combined with Escitalopram.
Repaglinide
Escitalopram may increase the hypoglycemic activities of Repaglinide.
Reproterol
Escitalopram may decrease the vasoconstricting activities of Reproterol.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Escitalopram.
Resveratrol
Escitalopram may increase the antiplatelet activities of Resveratrol.
Ribociclib
The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Escitalopram.
Rifabutin
The metabolism of Escitalopram can be increased when combined with Rifabutin.
Rifampin
The metabolism of Escitalopram can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Escitalopram can be increased when combined with Rifapentine.
Rilmenidine
Escitalopram may decrease the vasoconstricting activities of Rilmenidine.
Rilpivirine
Rilpivirine may increase the QTc-prolonging activities of Escitalopram.
Risperidone
The metabolism of Risperidone can be decreased when combined with Escitalopram.
Ritodrine
Escitalopram may decrease the vasoconstricting activities of Ritodrine.
Ritonavir
The metabolism of Escitalopram can be decreased when combined with Ritonavir.
Rizatriptan
The risk or severity of adverse effects can be increased when Rizatriptan is combined with Escitalopram.
Rofecoxib
Escitalopram may increase the antiplatelet activities of Rofecoxib.
Rolapitant
The metabolism of Escitalopram can be decreased when combined with Rolapitant.
Ropinirole
The metabolism of Escitalopram can be decreased when combined with Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Escitalopram.
Rosiglitazone
Escitalopram may increase the hypoglycemic activities of Rosiglitazone.
Rucaparib
The metabolism of Escitalopram can be decreased when combined with Rucaparib.
Salicylic Acid
Escitalopram may increase the antiplatelet activities of Salicylic acid.
Salmeterol
Salmeterol may increase the QTc-prolonging activities of Escitalopram.
Salsalate
Escitalopram may increase the antiplatelet activities of Salsalate.
Saquinavir
Saquinavir may increase the QTc-prolonging activities of Escitalopram.
Saquinavir Mesylate
Saquinavir may increase the QTc-prolonging activities of Escitalopram.
Sarilumab
The therapeutic efficacy of Escitalopram can be decreased when used in combination with Sarilumab.
Saxagliptin
Escitalopram may increase the hypoglycemic activities of Saxagliptin.
Saxagliptin Anhydrous
Escitalopram may increase the hypoglycemic activities of Saxagliptin.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.
Scopolamine Hydrobromide
The risk or severity of adverse effects can be increased when Scopolamine is combined with Escitalopram.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Escitalopram.
Selegiline
The risk or severity of adverse effects can be increased when Escitalopram is combined with Selegiline.
Sertindole
The risk or severity of adverse effects can be increased when Sertindole is combined with Escitalopram.
Sertraline
Sertraline may increase the serotonergic activities of Escitalopram.
Sevoflurane
Sevoflurane may increase the QTc-prolonging activities of Escitalopram.
Sildenafil
The metabolism of Escitalopram can be decreased when combined with Sildenafil.
Silodosin
Silodosin may increase the antihypertensive activities of Escitalopram.
Siltuximab
The serum concentration of Escitalopram can be decreased when it is combined with Siltuximab.
Simeprevir
The serum concentration of Simeprevir can be decreased when it is combined with Escitalopram.
Sitagliptin
Escitalopram may increase the hypoglycemic activities of Sitagliptin.
Sitagliptin Phosphate
Escitalopram may increase the hypoglycemic activities of Sitagliptin.
Sodium Oxybate
The risk or severity of adverse effects can be increased when Sodium oxybate is combined with Escitalopram.
Solifenacin
Solifenacin may increase the QTc-prolonging activities of Escitalopram.
Sorafenib
Sorafenib may increase the QTc-prolonging activities of Escitalopram.
Sotalol
The risk or severity of QTc prolongation can be increased when Sotalol is combined with Escitalopram.
ST. JOHN'S WORT EXTRACT
The serum concentration of Escitalopram can be decreased when it is combined with St. John's Wort.
Sufentanil
Sufentanil may increase the serotonergic activities of Escitalopram.
Sulfadiazine
Escitalopram may increase the hypoglycemic activities of Sulfadiazine.
Sulfamethoxazole
Sulfamethoxazole may increase the QTc-prolonging activities of Escitalopram.
Sulfasalazine
Escitalopram may increase the antiplatelet activities of Sulfasalazine.
Sulfisoxazole
Sulfisoxazole may increase the QTc-prolonging activities of Escitalopram.
Sulindac
Escitalopram may increase the antiplatelet activities of Sulindac.
Sulpiride
The risk or severity of adverse effects can be increased when Sulpiride is combined with Escitalopram.
Sumatriptan
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Escitalopram.
Sumatriptan Succinate
The risk or severity of adverse effects can be increased when Sumatriptan is combined with Escitalopram.
Sunitinib
Sunitinib may increase the QTc-prolonging activities of Escitalopram.
Suprofen
Escitalopram may increase the antiplatelet activities of Suprofen.
Suvorexant
The risk or severity of adverse effects can be increased when Suvorexant is combined with Escitalopram.
Synephrine
Escitalopram may decrease the vasoconstricting activities of Synephrine.
Tacrolimus
The metabolism of Tacrolimus can be decreased when combined with Escitalopram.
Tadalafil
Tadalafil may increase the hypotensive activities of Escitalopram.
Talinolol
Talinolol may increase the orthostatic hypotensive activities of Escitalopram.
Talniflumate
Escitalopram may increase the antiplatelet activities of Talniflumate.
Tamoxifen
Tamoxifen may increase the QTc-prolonging activities of Escitalopram.
Tamsulosin
Tamsulosin may increase the antihypertensive activities of Escitalopram.
Tapentadol
The risk or severity of adverse effects can be increased when Escitalopram is combined with Tapentadol.
Tasimelteon
The risk or severity of adverse effects can be increased when Tasimelteon is combined with Escitalopram.
Tedizolid
Tedizolid Phosphate may increase the serotonergic activities of Escitalopram.
Tedizolid Phosphate
Tedizolid Phosphate may increase the serotonergic activities of Escitalopram.
Telaprevir
The serum concentration of Escitalopram can be decreased when it is combined with Telaprevir.
Telavancin
Telavancin may increase the QTc-prolonging activities of Escitalopram.
Telithromycin
Telithromycin may increase the QTc-prolonging activities of Escitalopram.
Temazepam
The risk or severity of adverse effects can be increased when Temazepam is combined with Escitalopram.
Tenoxicam
Escitalopram may increase the antiplatelet activities of Tenoxicam.
Terazosin
Terazosin may increase the antihypertensive activities of Escitalopram.
Terbinafine
The metabolism of Escitalopram can be decreased when combined with Terbinafine.
Terbutaline
Terbutaline may increase the QTc-prolonging activities of Escitalopram.
Terbutaline Sulfate
Terbutaline may increase the QTc-prolonging activities of Escitalopram.
Tertatolol
Tertatolol may increase the orthostatic hypotensive activities of Escitalopram.
Tetrabenazine
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Tetrabenazine.
Tetracaine
The risk or severity of adverse effects can be increased when Tetracaine is combined with Escitalopram.
Tetracaine hydrochloride
The risk or severity of adverse effects can be increased when Tetracaine is combined with Escitalopram.
Tetrahydrozoline
Escitalopram may decrease the vasoconstricting activities of Tetryzoline.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Escitalopram.
Theophylline
Theophylline may increase the hypotensive activities of Escitalopram.
Theophylline anhydrous
Theophylline may increase the hypotensive activities of Escitalopram.
Thiamylal
The risk or severity of adverse effects can be increased when Thiamylal is combined with Escitalopram.
Thiethylperazine
The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Escitalopram.
Thiopental
The risk or severity of adverse effects can be increased when Thiopental is combined with Escitalopram.
Thiopental Sodium
The risk or severity of adverse effects can be increased when Thiopental is combined with Escitalopram.
Thioproperazine
Escitalopram may increase the antihypertensive activities of Thioproperazine.
Thioridazine
The serum concentration of Thioridazine can be increased when it is combined with Escitalopram.
Thiothixene
Thiothixene may increase the QTc-prolonging activities of Escitalopram.
Thyroid, Porcine
The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Escitalopram.
Tiagabine
The risk or severity of adverse effects can be increased when Tiagabine is combined with Escitalopram.
Tianeptine
The risk or severity of adverse effects can be increased when Tianeptine is combined with Escitalopram.
Tiapride
The risk or severity of adverse effects can be increased when Tiapride is combined with Escitalopram.
Tiaprofenic Acid
Escitalopram may increase the antiplatelet activities of Tiaprofenic acid.
Ticlopidine
The metabolism of Escitalopram can be decreased when combined with Ticlopidine.
Timolol
Timolol may increase the orthostatic hypotensive activities of Escitalopram.
Timolol Anhydrous
Timolol may increase the orthostatic hypotensive activities of Escitalopram.
Tipranavir
The metabolism of Escitalopram can be decreased when combined with Tipranavir.
Tizanidine
Tizanidine may increase the QTc-prolonging activities of Escitalopram.
Tocilizumab
The serum concentration of Escitalopram can be decreased when it is combined with Tocilizumab.
Tolazamide
Escitalopram may increase the hypoglycemic activities of Tolazamide.
Tolazoline
Tolazoline may increase the antihypertensive activities of Escitalopram.
Tolbutamide
Escitalopram may increase the hypoglycemic activities of Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Escitalopram.
Tolfenamic Acid
The risk or severity of hypotension can be increased when Escitalopram is combined with Tolfenamic Acid.
Tolmetin
Escitalopram may increase the antiplatelet activities of Tolmetin.
Toloxatone
Toloxatone may increase the serotonergic activities of Escitalopram.
Tolterodine
Tolterodine may increase the QTc-prolonging activities of Escitalopram.
Topiramate
The metabolism of Escitalopram can be decreased when combined with Topiramate.
Toremifene
The risk or severity of QTc prolongation can be increased when Toremifene is combined with Escitalopram.
Tramadol
Escitalopram may increase the neuroexcitatory activities of Tramadol.
Tranilast
The risk or severity of hypotension can be increased when Escitalopram is combined with Tranilast.
Tranylcypromine
The risk or severity of adverse effects can be increased when Escitalopram is combined with Tranylcypromine.
Trazodone
Trazodone may increase the antihypertensive activities of Escitalopram.
Treprostinil
Treprostinil may increase the QTc-prolonging activities of Escitalopram.
Triamcinolone
Escitalopram may increase the antiplatelet activities of Triamcinolone.
Triazolam
The risk or severity of adverse effects can be increased when Triazolam is combined with Escitalopram.
Triazulenone
The risk or severity of adverse effects can be increased when Loprazolam is combined with Escitalopram.
Trichlormethiazide
Escitalopram may increase the hyponatremic activities of Trichlormethiazide.
Trifluoperazine
Trifluoperazine may increase the antihypertensive activities of Escitalopram.
Triflupromazine
The risk or severity of adverse effects can be increased when Triflupromazine is combined with Escitalopram.
Trimebutine
The risk or severity of hypotension can be increased when Escitalopram is combined with Trimebutine.
Trimeprazine
The risk or severity of adverse effects can be increased when Alimemazine is combined with Escitalopram.
Trimethadione
The risk or severity of hypotension can be increased when Escitalopram is combined with Trimethadione.
Trimethoprim
Trimethoprim may increase the QTc-prolonging activities of Escitalopram.
Trimipramine
The risk or severity of adverse effects can be increased when Trimipramine is combined with Escitalopram.
Triprolidine
The risk or severity of adverse effects can be increased when Triprolidine is combined with Escitalopram.
Triptorelin
Triptorelin may increase the QTc-prolonging activities of Escitalopram.
Trolamine Salicylate
Escitalopram may increase the antiplatelet activities of Trolamine salicylate.
Tropisetron
Tropisetron may increase the serotonergic activities of Escitalopram.
Tryptophan
L-Tryptophan may increase the serotonergic activities of Escitalopram.
Tulobuterol
Escitalopram may decrease the vasoconstricting activities of Tulobuterol.
Urapidil
Urapidil may increase the antihypertensive activities of Escitalopram.
Urethane
The risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Escitalopram.
Valdecoxib
Escitalopram may increase the antiplatelet activities of Valdecoxib.
Valproate
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Escitalopram.
Valproic Acid
The risk or severity of adverse effects can be increased when Valproic Acid is combined with Escitalopram.
Vandetanib
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Vandetanib.
Vardenafil
Vardenafil may increase the QTc-prolonging activities of Escitalopram.
Vemurafenib
The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Escitalopram.
Venlafaxine
Venlafaxine may increase the serotonergic activities of Escitalopram.
Verapamil
Escitalopram may increase the antihypertensive activities of Verapamil.
Vigabatrin
The risk or severity of adverse effects can be increased when Vigabatrin is combined with Escitalopram.
Vilanterol
Vilanterol may increase the QTc-prolonging activities of Escitalopram.
Vilazodone
Escitalopram may increase the serotonergic activities of Vilazodone.
Vinpocetine
The risk or severity of hypotension can be increased when Escitalopram is combined with Vinpocetine.
Voriconazole
The metabolism of Escitalopram can be decreased when combined with Voriconazole.
Vorinostat
Vorinostat may increase the QTc-prolonging activities of Escitalopram.
Vortioxetine
Escitalopram may increase the serotonergic activities of Vortioxetine.
Warfarin
Escitalopram may increase the anticoagulant activities of Warfarin.
Xamoterol
Escitalopram may decrease the vasoconstricting activities of Xamoterol.
Xylazine
The risk or severity of adverse effects can be increased when Xylazine is combined with Escitalopram.
Xylometazoline
Escitalopram may decrease the vasoconstricting activities of Xylometazoline.
Zaleplon
The risk or severity of adverse effects can be increased when Zaleplon is combined with Escitalopram.
Ziconotide
The risk or severity of adverse effects can be increased when Ziconotide is combined with Escitalopram.
Ziprasidone
The metabolism of Escitalopram can be decreased when combined with Ziprasidone.
Zolmitriptan
The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Escitalopram.
Zolpidem
The risk or severity of adverse effects can be increased when Zolpidem is combined with Escitalopram.
Zonisamide
The risk or severity of adverse effects can be increased when Zonisamide is combined with Escitalopram.
Zopiclone
The risk or severity of adverse effects can be increased when Zopiclone is combined with Escitalopram.
Zotepine
The risk or severity of adverse effects can be increased when Zotepine is combined with Escitalopram.
Zuclopenthixol
The risk or severity of QTc prolongation can be increased when Escitalopram is combined with Zuclopenthixol.
